292 related articles for article (PubMed ID: 17583355)
21. Effects of clozapine and N-desmethylclozapine on synaptic transmission at hippocampal inhibitory and excitatory synapses.
Ohno-Shosaku T; Sugawara Y; Muranishi C; Nagasawa K; Kubono K; Aoki N; Taguchi M; Echigo R; Sugimoto N; Kikuchi Y; Watanabe R; Yoneda M
Brain Res; 2011 Nov; 1421():66-77. PubMed ID: 21945084
[TBL] [Abstract][Full Text] [Related]
22. Neuroleptic binding to human brain receptors: relation to clinical effects.
Richelson E
Ann N Y Acad Sci; 1988; 537():435-42. PubMed ID: 2904784
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacology of neuroleptics: focus on new generation compounds.
Richelson E
J Clin Psychiatry; 1996; 57 Suppl 11():4-11. PubMed ID: 8941166
[TBL] [Abstract][Full Text] [Related]
24. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
Weiner DM; Meltzer HY; Veinbergs I; Donohue EM; Spalding TA; Smith TT; Mohell N; Harvey SC; Lameh J; Nash N; Vanover KE; Olsson R; Jayathilake K; Lee M; Levey AI; Hacksell U; Burstein ES; Davis RE; Brann MR
Psychopharmacology (Berl); 2004 Dec; 177(1-2):207-16. PubMed ID: 15258717
[TBL] [Abstract][Full Text] [Related]
25. The relationship between plasma levels of clozapine and N-desmethyclozapine as well as M1 receptor polymorphism with cognitive functioning and associated cortical activity in schizophrenia.
Kır Y; Baskak B; Kuşman A; Sayar-Akaslan D; Özdemir F; Sedes-Baskak N; Süzen HS; Baran Z
Psychiatry Res Neuroimaging; 2020 Sep; 303():111128. PubMed ID: 32593951
[TBL] [Abstract][Full Text] [Related]
26. New insights into the biology of schizophrenia through the mechanism of action of clozapine.
Brunello N; Masotto C; Steardo L; Markstein R; Racagni G
Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893
[TBL] [Abstract][Full Text] [Related]
27. Behavioral pharmacology of olanzapine: a novel antipsychotic drug.
Moore NA; Leander JD; Benvenga MJ; Gleason SD; Shannon H
J Clin Psychiatry; 1997; 58 Suppl 10():37-44. PubMed ID: 9265915
[TBL] [Abstract][Full Text] [Related]
28. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine.
Rajji TK; Mulsant BH; Davies S; Kalache SM; Tsoutsoulas C; Pollock BG; Remington G
Am J Psychiatry; 2015 Jun; 172(6):579-85. PubMed ID: 25859763
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
Burstein ES; Ma J; Wong S; Gao Y; Pham E; Knapp AE; Nash NR; Olsson R; Davis RE; Hacksell U; Weiner DM; Brann MR
J Pharmacol Exp Ther; 2005 Dec; 315(3):1278-87. PubMed ID: 16135699
[TBL] [Abstract][Full Text] [Related]
30. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
31. Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.
Sarpal DK; Blazer A; Wilson JD; Calabro FJ; Foran W; Kahn CE; Luna B; Chengappa KNR
Schizophr Res; 2022 May; 243():170-177. PubMed ID: 35381515
[TBL] [Abstract][Full Text] [Related]
32. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy of schizophrenia: a review.
Sigmundson HK
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S70-5. PubMed ID: 7533053
[TBL] [Abstract][Full Text] [Related]
34. [Treatment-resistant schizophrenia].
Yahyaten OB
Rev Med Brux; 2014; 35(3):169-73. PubMed ID: 25102584
[TBL] [Abstract][Full Text] [Related]
35. Prospects for pharmacotherapy of schizophrenia.
Pickar D
Lancet; 1995 Mar; 345(8949):557-62. PubMed ID: 7539875
[No Abstract] [Full Text] [Related]
36. Clozapine-induced salivation: interaction with N-desmethylclozapine and amisulpride in an experimental rat model.
Godoy T; Riva A; Ekström J
Eur J Oral Sci; 2011 Aug; 119(4):275-81. PubMed ID: 21726287
[TBL] [Abstract][Full Text] [Related]
37. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain.
Kanba S; Yagi G; Oguchi E; Nakaki T; Kato R; Richelson E
Jpn J Psychiatry Neurol; 1991 Mar; 45(1):133-4. PubMed ID: 1684393
[No Abstract] [Full Text] [Related]
38. [How do clozapine and co. work? Pharmacologic mechanisms of atypical neuroleptics].
Müller WE
Pharm Unserer Zeit; 2002; 31(6):537-45. PubMed ID: 12481511
[No Abstract] [Full Text] [Related]
39. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
Millan MJ
J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
[TBL] [Abstract][Full Text] [Related]
40. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy].
Ewald HL; Mors NP; Rosenberg R
Ugeskr Laeger; 1996 Jun; 158(25):3601-3. PubMed ID: 8693618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
